CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
quetiapinedrug
Likely dose
quetiapine 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00954681
NCT00954681Phase 2Completed
CompareCT.gov

Open-Label Pilot Study of Quetiapine Treatment for Cannabis Dependence

New York State Psychiatric Institute·interventional·Posted Aug 7, 2009·Updated Apr 24, 2019

In Brief

A Phase 2 clinical trial evaluating quetiapine for Cannabis Dependence. Completed, enrolled 15 participants across 1 site.

Detailed Summary

Marijuana is the most commonly used illicit drug in the United States. However, the treatment options for cannabis dependence are limited; notably, no effective pharmacotherapy has been developed. Conceptually, the ideal medication treatment for cannabis dependence would: 1. be safe when administered to patients actively using cannabis 2. reduce cannabis intake and promote abstinence 3. treat the symptoms of cannabis withdrawal 4. reduce craving and relapse risk 5. have a low abuse liability.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 7, 2009
Enrollment StartAug 1, 2009
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.9 years ago

Interventions

quetiapinedrug

Quetiapine treatment from 25 mg daily to 300 mg twice daily